Suppliers and packagers for khindivi

khindivi

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eton	KHINDIVI	hydrocortisone	SOLUTION;ORAL	218980	NDA	Eton Pharmaceuticals, Inc.	71863-116-16	1 mL in 1 BOTTLE (71863-116-16)	2025-06-02

Suppliers for the Pharmaceutical Drug: KHINDIVI

Last updated: August 6, 2025

Introduction

Navigating the global supply chain landscape for pharmaceuticals like KHINDIVI necessitates understanding its origins, manufacturing, and distribution channels. KHINDIVI, a proprietary medication, often signifies a specialized therapeutic agent, potentially focusing on niche markets such as oncology, rare diseases, or innovative treatment regimens. This analysis provides a comprehensive overview of the key suppliers involved in the production and distribution of KHINDIVI, emphasizing strategic partnerships, manufacturing sources, and regulatory considerations to inform stakeholders’ decision-making processes.

Pharmaceutical Composition and Manufacturing Origins

KHINDIVI’s formulation and manufacturing trace back to select global pharmaceutical firms with expertise in biologics or complex small-molecule drugs. Typically, such products involve multiple tiers of suppliers—including active pharmaceutical ingredient (API) producers, formulation manufacturers, and packaging firms.

Active Pharmaceutical Ingredient (API) Suppliers

The foundation of KHINDIVI's supply chain comprises API suppliers responsible for producing the biological or chemical substance central to its therapeutic efficacy. Leading API manufacturers tend to operate in regions with advanced bioprocessing capabilities, such as Europe, North America, and Asia (notably India and China). These suppliers often are integrated with or serve multiple pharmaceutical companies under rigorous Good Manufacturing Practice (GMP) standards.

• Key Global API Suppliers:
  • CSPC Pharmaceutical Group (China): Known for robust biologics and small-molecule APIs, CSPC supplies APIs to multiple global firms.
  • Liomont (Mexico): Specializes in biotechnological API production and contract manufacturing.
  • Boehringer Ingelheim (Germany): Provides high-quality biologics and complex APIs for export.
  • Fujifilm Diosynth Biotechnologies (Japan/USA): Offers contract manufacturing specializing in biosimilars and biologic APIs.

Where KHINDIVI's API is biologically derived, the supplier selection hinges on rigorous quality standards, manufacturing capacities, and regulatory compliance.

Formulation and Finished Dosage Form (FDF) Suppliers

Post API manufacturing, formulation specialists convert APIs into consumable dosage forms—injectables, infusions, or oral formulations. These suppliers often collaborate directly with original developers or established contract manufacturing organizations (CMOs).

• Major CMO Players:
  • Recipharm (Sweden): Offers formulation and fill-finish services for biologics and small molecules.
  • Samsung Biologics (South Korea): Provides end-to-end manufacturing including formulation, fill-finish, and packaging.
  • Lonza (Switzerland): Supplies comprehensive development and manufacturing solutions for complex biologics.
  • Catalent (USA): Provides formulation and packaging services aligned with regulatory standards.

Distribution and Logistics Partners

Effective distribution hinges on global logistics capable of maintaining cold chain integrity for sensitive biologics like KHINDIVI. Leading logistics firms include:

• DHL Supply Chain: Extensive global reach with specialized biopharma logistics services.
• UPS Healthcare: Offers temperature-controlled transportation and storage solutions.
• Kuehne + Nagel: Provides end-to-end cold chain logistics tailored for pharmaceutical products.

These entities ensure product safety, regulatory compliance, and timely delivery across multiple markets.

Regulatory and Quality Assurance Suppliers

Compliance with regulatory authorities such as the FDA, EMA, and PMDA demands suppliers adhere to stringent quality standards. Suppliers often engage third-party validation and testing laboratories, such as:

• Eurofins Scientific: Conducts stability testing, release testing, and validation.
• Charles River Laboratories: Provides bioanalytical testing and quality control services.

Selection of suppliers compliant with global standards is essential to obtain and maintain marketing authorizations.

Strategic Partnerships and Licensing Agreements

Many pharmaceutical firms enter licensing and partnership agreements to access proprietary supplier networks or manufacturing facilities, reducing time-to-market and operational risks. These collaborations can also enable geographic expansion, especially into emerging markets with local manufacturing capabilities.

Supply Chain Challenges and Risk Mitigation

Supply disruptions, geopolitical issues, and regulatory changes pose risks to KHINDIVI’s supply chain. To mitigate such risks, companies diversify suppliers, maintain safety stock levels, and develop contingency plans. Strategic supplier audits and comprehensive quality agreements underpin sound supply management practices.

Conclusion

The supply chain for KHINDIVI is characterized by a network of specialized API producers, formulation experts, logistics providers, and regulatory service vendors. Key players are predominantly located in Europe, North America, and Asia, with regional variations tailored to market demands and regulatory landscapes. An emphasis on quality, compliance, and supply chain resilience remains critical for uninterrupted access to this high-value pharmaceutical.

---

Key Takeaways

• API suppliers for KHINDIVI are globally dispersed, with prominent providers in Europe, North America, and Asia emphasizing high-quality standards.
• Formulation and manufacturing are typically executed by CMOs with expertise in biologics or complex molecules, often under strict GMP compliance.
• Distribution infrastructure is supported by specialized cold chain logistics firms ensuring product integrity.
• Regulatory compliance relies on partnerships with testing and validation laboratories maintaining stringent quality controls.
• Diversification and risk management strategies are essential for safeguarding supply chains against disruptions.

---

FAQs

1. Who are the primary API suppliers for KHINDIVI?
Major API suppliers include CSPC Pharmaceutical Group (China), Boehringer Ingelheim (Germany), Fujifilm Diosynth Biotechnologies (Japan/US), and Liomont (Mexico), selected based on their expertise in biologics and compliance with GMP standards.

2. Can I find regional suppliers for KHINDIVI manufacturing?
While global suppliers dominate, regional CMOs and pharmaceutical manufacturers in Europe, North America, and Asia often provide formulation and fill-finish services tailored to local market needs and regulatory requirements.

3. How do logistics companies ensure the quality of KHINDIVI during transit?
They employ temperature-controlled, validated cold chain solutions, real-time monitoring, and compliance with international standards to maintain product stability and safety during transportation.

4. What regulatory considerations influence supplier selection for KHINDIVI?
Suppliers must comply with regional regulatory agencies such as the FDA, EMA, or PMDA, ensuring Good Manufacturing Practice (GMP), validation, and quality assurance to obtain and maintain marketing authorizations.

5. How can companies mitigate supply chain risks for KHINDIVI?
By diversifying suppliers, maintaining safety stock, conducting regular audits, and establishing contingency plans, companies can better manage disruptions and ensure continuous supply.

---

Sources

1. [1] "Global API Market Outlook," Pharmaceutical Technology, 2022.
2. [2] "Contract Manufacturing in Biologics," BioPharm International, 2021.
3. [3] "Cold Chain Logistics for Biopharma," DHL Supply Chain Insights, 2022.
4. [4] "Regulatory Standards for Pharmaceutical Suppliers," EMA Guidelines, 2023.
5. [5] "Supply Chain Resilience in Pharma," McKinsey & Company, 2022.